Results 171 to 180 of about 83,505 (263)

Pharma steps back from Hodgkin lymphoma: now what? [PDF]

Blood Adv
Lynch RC, Gopal AK.
europepmc   +1 more source

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra, Cecile Wasielewski, Bruno Špiljak, Maja Sabalić‐Schoener, Sebastien Jungo, Ivan Alajbeg   +5 more
wiley   +1 more source

Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma. [PDF]

Expert Opin Investig Drugs
Pagès-Geli C, Weiskopf K.
europepmc   +1 more source

Systemic effects of sunlight: 10‐year review of cardiovascular, infection and cancer outcomes

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review highlights the systemic effects of sunlight and ultraviolet radiation. While UV radiation exposure has known cutaneous risks including photoaging and skin cancer, evidence suggests potential associations with reduced all‐cause mortality, improved infectious disease outcomes and reduced blood pressure.
Jasira A. Ziglar, Rebecca L. Quiñonez, Lydiah Fridah M. Mpyisi, Indermeet Kohli, Yolanda Gilaberte, Henry W. Lim   +5 more
wiley   +1 more source

A proimmunotoxin nanodrug targeting AIDS-associated non-Hodgkin lymphoma. [PDF]

J Control Release
Chen S, Qi T, Peng H, Kimura E, Zhang X, Kranz E, Cao Z, Wang Z, Chen W, Ancheta LR, Lappi DA, Chiou PY, Lu Y, Daniels-Wells TR, Penichet ML, Wen J.   +15 more
europepmc   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors. [PDF]

Br J Haematol
Argnani L, Stefoni V, Casadei B, Pelusi C, Preiato VL, Pagotto U, Buganè A, Pellegrini C, Broccoli A, Zinzani PL.   +9 more
europepmc   +1 more source

Porphyromonas gingivalis GroEL exacerbates orthotopic allograft transplantation vasculopathy via impairment of endothelial cell function

Molecular Oral Microbiology, EarlyView.
Abstract Orthotopic allograft transplantation (OAT) is a significant approach to addressing organ failure. However, persistent immune responses to the allograft affect chronic rejection, which induces OAT vasculopathy (OATV) and organ failure. Porphyromonas gingivalis can infiltrate remote organs via the bloodstream, thereby intensifying the severity ...
Chien‐Sung Tsai, Chun‐Yao Huang, Yi‐Ting Tsai, Chun‐Ming Shih, Ze‐Hao Lai, Chen‐Wei Liu, Yi‐Wen Lin, Feng‐Yen Lin   +7 more
wiley   +1 more source

Paraneoplastic Hepatitis Associated with Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. [PDF]

Hematol Rep
Nelissen J, Coenen S, Lam K, Doukas M, Janssen HLA, Serroukh Y.   +5 more
europepmc   +1 more source

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy. [PDF]

J Adv Pract Oncol
Guerrero MD.
europepmc   +1 more source